Comparison · NCT04817332-556a0849
Brensocatib vs Placebo: Discontinuation or Temporary Suspension of Treatment
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Brensocatib vs Placebo: Discontinuation or Temporary Suspension of Treatment. Trial comparisons, record NCT04817332-556a0849. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04817332-556a0849
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0677 | 0.04 | 0.112 | wilson | |
| Risk in group 2 | 0.0561 | 0.0324 | 0.0954 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0116 | -0.0365 | 0.0622 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.21 | 0.565 | 2.58 | log | |
| Odds ratio, group 1 over group 2 | 1.22 | 0.544 | 2.75 | log | |
| Number needed to treat, for one more participant with the outcome on Brensocatib than on Placebo | 86 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Brensocatib | Brensocatib oral tablet, 25mg once per day for 28 days~Brensocatib: Selective, competitive, and reversible inhibitor of DPP1 | 13 | 192 | OG000 |
| Group 2 | Placebo | Placebo oral tablet, 25mg once per day for 28 days~Placebo: Matched placebo | 12 | 214 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Discontinuation or Temporary Suspension of Treatment
- Description
- Evaluation of the safety of the intervention through 28 days of follow-up as compared to the control arm
- Time frame
- 1-29 days
- Population
- Safety
Source ClinicalTrials.gov
Trial
- Title
- STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19
- NCT number
- NCT04817332
- Phases
- PHASE3
- Conditions
- Covid19
- Interventions
- Brensocatib, Placebo
- Lead sponsor
- University of Dundee
- Results first posted
- 2023-08-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04817332?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04817332-556a0849